| . | Total . | RA . | PsA . | axSpA . | Undifferentiated arthritis . | Other . |
|---|---|---|---|---|---|---|
| . | N = 14 007 . | N = 9729 . | N = 1804 . | N = 272 . | N = 1661 . | N = 541 . |
| No DMARD, n (%) | 2866 (21) | 1223 (13) | 452 (26) | 201 (80) | 689 (43) | 301 (60) |
| MTX, n (%) | ||||||
| MTX monotherapy | 6008 (44) | 4591 (48) | 954 (56) | 13 (5) | 385 (24) | 65 (13) |
| MTX combination | 1346 (10) | 1253 (13) | 25 (1) | 7 (3) | 54 (3) | 7 (1) |
| SSZ, n (%) | ||||||
| SSZ monotherapy | 1280 (9) | 798 (8) | 224 (13) | 10 (4) | 202 (13) | 46 (9) |
| SSZ combination | 244 (2) | 207 (2) | 15 (1) | 3 (1) | 17 (1) | 2 (0) |
| HCQ, n (%) | ||||||
| HCQ monotherapy | 1813 (13) | 1450 (15) | 27 (2) | 8 (3) | 254 (16) | 74 (15) |
| HCQ combination | 1352 (10) | 1282 (14) | 7 (0) | 4 (2) | 51 (3) | 8 (2) |
| Missing treatment information, n | 351 | 236 | 91 | 21 | 57 | 37 |
| Corticosteroids, n (%) | ||||||
| No | 4080 (30) | 2096 (22) | 882 (51) | 195 (79) | 632 (40) | 275 (55) |
| Yes | 9513 (70) | 7417 (78) | 851 (49) | 51 (21) | 968 (60) | 226 (45) |
| Missing steroid information, n | 414 | 216 | 71 | 26 | 61 | 40 |
| . | Total . | RA . | PsA . | axSpA . | Undifferentiated arthritis . | Other . |
|---|---|---|---|---|---|---|
| . | N = 14 007 . | N = 9729 . | N = 1804 . | N = 272 . | N = 1661 . | N = 541 . |
| No DMARD, n (%) | 2866 (21) | 1223 (13) | 452 (26) | 201 (80) | 689 (43) | 301 (60) |
| MTX, n (%) | ||||||
| MTX monotherapy | 6008 (44) | 4591 (48) | 954 (56) | 13 (5) | 385 (24) | 65 (13) |
| MTX combination | 1346 (10) | 1253 (13) | 25 (1) | 7 (3) | 54 (3) | 7 (1) |
| SSZ, n (%) | ||||||
| SSZ monotherapy | 1280 (9) | 798 (8) | 224 (13) | 10 (4) | 202 (13) | 46 (9) |
| SSZ combination | 244 (2) | 207 (2) | 15 (1) | 3 (1) | 17 (1) | 2 (0) |
| HCQ, n (%) | ||||||
| HCQ monotherapy | 1813 (13) | 1450 (15) | 27 (2) | 8 (3) | 254 (16) | 74 (15) |
| HCQ combination | 1352 (10) | 1282 (14) | 7 (0) | 4 (2) | 51 (3) | 8 (2) |
| Missing treatment information, n | 351 | 236 | 91 | 21 | 57 | 37 |
| Corticosteroids, n (%) | ||||||
| No | 4080 (30) | 2096 (22) | 882 (51) | 195 (79) | 632 (40) | 275 (55) |
| Yes | 9513 (70) | 7417 (78) | 851 (49) | 51 (21) | 968 (60) | 226 (45) |
| Missing steroid information, n | 414 | 216 | 71 | 26 | 61 | 40 |
Early treatment strategy used in patients with EIA in England recruited to NEIAA. Individuals were considered at risk from February 2020 (date of first case of COVID-19 in NEIAA) or date of diagnosis (whichever was later) and censored at a COVID-19 event, May 2021 or death (whichever was sooner). EIA: early inflammatory arthritis; NEIAA: National Early Inflammatory Arthritis Audit; n: number of patients; COVID-19: coronavirus disease 2019.
| . | Total . | RA . | PsA . | axSpA . | Undifferentiated arthritis . | Other . |
|---|---|---|---|---|---|---|
| . | N = 14 007 . | N = 9729 . | N = 1804 . | N = 272 . | N = 1661 . | N = 541 . |
| No DMARD, n (%) | 2866 (21) | 1223 (13) | 452 (26) | 201 (80) | 689 (43) | 301 (60) |
| MTX, n (%) | ||||||
| MTX monotherapy | 6008 (44) | 4591 (48) | 954 (56) | 13 (5) | 385 (24) | 65 (13) |
| MTX combination | 1346 (10) | 1253 (13) | 25 (1) | 7 (3) | 54 (3) | 7 (1) |
| SSZ, n (%) | ||||||
| SSZ monotherapy | 1280 (9) | 798 (8) | 224 (13) | 10 (4) | 202 (13) | 46 (9) |
| SSZ combination | 244 (2) | 207 (2) | 15 (1) | 3 (1) | 17 (1) | 2 (0) |
| HCQ, n (%) | ||||||
| HCQ monotherapy | 1813 (13) | 1450 (15) | 27 (2) | 8 (3) | 254 (16) | 74 (15) |
| HCQ combination | 1352 (10) | 1282 (14) | 7 (0) | 4 (2) | 51 (3) | 8 (2) |
| Missing treatment information, n | 351 | 236 | 91 | 21 | 57 | 37 |
| Corticosteroids, n (%) | ||||||
| No | 4080 (30) | 2096 (22) | 882 (51) | 195 (79) | 632 (40) | 275 (55) |
| Yes | 9513 (70) | 7417 (78) | 851 (49) | 51 (21) | 968 (60) | 226 (45) |
| Missing steroid information, n | 414 | 216 | 71 | 26 | 61 | 40 |
| . | Total . | RA . | PsA . | axSpA . | Undifferentiated arthritis . | Other . |
|---|---|---|---|---|---|---|
| . | N = 14 007 . | N = 9729 . | N = 1804 . | N = 272 . | N = 1661 . | N = 541 . |
| No DMARD, n (%) | 2866 (21) | 1223 (13) | 452 (26) | 201 (80) | 689 (43) | 301 (60) |
| MTX, n (%) | ||||||
| MTX monotherapy | 6008 (44) | 4591 (48) | 954 (56) | 13 (5) | 385 (24) | 65 (13) |
| MTX combination | 1346 (10) | 1253 (13) | 25 (1) | 7 (3) | 54 (3) | 7 (1) |
| SSZ, n (%) | ||||||
| SSZ monotherapy | 1280 (9) | 798 (8) | 224 (13) | 10 (4) | 202 (13) | 46 (9) |
| SSZ combination | 244 (2) | 207 (2) | 15 (1) | 3 (1) | 17 (1) | 2 (0) |
| HCQ, n (%) | ||||||
| HCQ monotherapy | 1813 (13) | 1450 (15) | 27 (2) | 8 (3) | 254 (16) | 74 (15) |
| HCQ combination | 1352 (10) | 1282 (14) | 7 (0) | 4 (2) | 51 (3) | 8 (2) |
| Missing treatment information, n | 351 | 236 | 91 | 21 | 57 | 37 |
| Corticosteroids, n (%) | ||||||
| No | 4080 (30) | 2096 (22) | 882 (51) | 195 (79) | 632 (40) | 275 (55) |
| Yes | 9513 (70) | 7417 (78) | 851 (49) | 51 (21) | 968 (60) | 226 (45) |
| Missing steroid information, n | 414 | 216 | 71 | 26 | 61 | 40 |
Early treatment strategy used in patients with EIA in England recruited to NEIAA. Individuals were considered at risk from February 2020 (date of first case of COVID-19 in NEIAA) or date of diagnosis (whichever was later) and censored at a COVID-19 event, May 2021 or death (whichever was sooner). EIA: early inflammatory arthritis; NEIAA: National Early Inflammatory Arthritis Audit; n: number of patients; COVID-19: coronavirus disease 2019.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
